Clinical Trials List
Protocol NumberASLAN001-008
NCT Number(ClinicalTrials.gov Identfier)NCT03231176
2018-04-20 - 2019-03-26
Phase II
Terminated3
ICD-10C22.1
Intrahepatic bile duct carcinoma
ICD-10C24.9
Malignant neoplasm of biliary tract, unspecified
ICD-9156.9
Malignant neoplasm of biliary tract, part unspecified
A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy
-
Trial Applicant
Syneos Health
-
Sponsor
ASLAN Pharmaceuticals Pte. Ltd
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Rheun-Chuan Lee Division of Pediatrics
- Ming-Huang Chen Division of Hematology & Oncology
- Chung-Pin Li Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 吳旭 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 魯維丞 Division of Hematology & Oncology
- FU-JEN HSUEH Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Linkou Chang Gung Medical Foundation
Taiwan National PI
陳仁熙
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Condition/Disease
Biliary Tract Cancer
Objectives
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors. The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer. Eligible patients will receive Varlitinib plus capecitabine.
Test Drug
varlitinib
Active Ingredient
varlitinib
Dosage Form
Tablets
Dosage
100
Endpoints
Primary Outcome Measures :
Objective Response Rate (ORR) [ Time Frame: Through study duration, estimated 2 years ]
Objective Response Rate defined as the proportion of patients with a confirmed best response of partial response (PR) or complete response (CR), as defined by RECIST v1.1 criteria, based on an Independent Central Review (ICR) of radiological data.
Secondary Outcome Measures :
Progression-free survival (PFS) [ Time Frame: Through study duration, estimated 2 years ]
Progression Free Survival defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived using data from the ICR.
Disease Control Rate (DCR) [ Time Frame: Through study duration, estimated 2 years ]
Disease control rate is defined as the number (%) of patients with a confirmed response of CR or PR, or with stable disease for a minimum of twelve weeks (- 5 days) from starting treatment.
Duration of Response (DoR) [ Time Frame: Through study duration, estimated 2 years ]
The Duration of Response is defined as the time from the date of first documented response until the date of documented disease progression or death in the absence of disease progression, in the subset of patient classified as confirmed responders for the assessment of ORR. The end of response should coincide with the date of disease progression or death from any cause used for the PFS endpoint. DoR will be calculated using the ICR data.
Overall Survival (OS) [ Time Frame: Through study duration, estimated 2 years ]
Overall Survival is defined as time from the start of treatment until death by any cause.
Safety and tolerability of varlitinib when combined with capecitabine [ Time Frame: Through study duration, estimated 2 years ]
Incidence of AEs, categorized in accordance to CTCAE 4.03, and changes from baseline in safety parameters
Objective Response Rate (ORR) [ Time Frame: Through study duration, estimated 2 years ]
Objective Response Rate defined as the proportion of patients with a confirmed best response of partial response (PR) or complete response (CR), as defined by RECIST v1.1 criteria, based on an Independent Central Review (ICR) of radiological data.
Secondary Outcome Measures :
Progression-free survival (PFS) [ Time Frame: Through study duration, estimated 2 years ]
Progression Free Survival defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived using data from the ICR.
Disease Control Rate (DCR) [ Time Frame: Through study duration, estimated 2 years ]
Disease control rate is defined as the number (%) of patients with a confirmed response of CR or PR, or with stable disease for a minimum of twelve weeks (- 5 days) from starting treatment.
Duration of Response (DoR) [ Time Frame: Through study duration, estimated 2 years ]
The Duration of Response is defined as the time from the date of first documented response until the date of documented disease progression or death in the absence of disease progression, in the subset of patient classified as confirmed responders for the assessment of ORR. The end of response should coincide with the date of disease progression or death from any cause used for the PFS endpoint. DoR will be calculated using the ICR data.
Overall Survival (OS) [ Time Frame: Through study duration, estimated 2 years ]
Overall Survival is defined as time from the start of treatment until death by any cause.
Safety and tolerability of varlitinib when combined with capecitabine [ Time Frame: Through study duration, estimated 2 years ]
Incidence of AEs, categorized in accordance to CTCAE 4.03, and changes from baseline in safety parameters
Inclution Criteria
Inclusion Criteria:
Patients with histologically or cytologically confirmed advanced (unresectable) or metastatic biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and carcinoma of the Ampulla of Vater. This includes clinical diagnosis of biliary tract cancer with histological confirmation of adenocarcinoma.
Patients who have received and failed one and only one prior line of systemic treatment or advanced or metastatic disease with radiologic evidence of disease progression. This prior line of systemic treatment must also contain gemcitabine
Patients with radiographically measurable disease based on RECIST v1.1.
Patients with no evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN).
Patients who are or older than 18 years of age and of or younger than 99 years of age at the time when written informed consent is obtained, and are able to understand and willing to sign the informed consent form.
Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients with adequate organ and hematological function:
Hematological function, as follows:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x 109/L
Renal functions, as follows:
Estimated glomerular filtration rate or creatinine clearance > 50 mL/min/1.73m2
Hepatic function, as follows:
Total bilirubin ≤ 1.5 x ULN
AST and ALT ≤ 5 x ULN
Patients with histologically or cytologically confirmed advanced (unresectable) or metastatic biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and carcinoma of the Ampulla of Vater. This includes clinical diagnosis of biliary tract cancer with histological confirmation of adenocarcinoma.
Patients who have received and failed one and only one prior line of systemic treatment or advanced or metastatic disease with radiologic evidence of disease progression. This prior line of systemic treatment must also contain gemcitabine
Patients with radiographically measurable disease based on RECIST v1.1.
Patients with no evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN).
Patients who are or older than 18 years of age and of or younger than 99 years of age at the time when written informed consent is obtained, and are able to understand and willing to sign the informed consent form.
Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients with adequate organ and hematological function:
Hematological function, as follows:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x 109/L
Renal functions, as follows:
Estimated glomerular filtration rate or creatinine clearance > 50 mL/min/1.73m2
Hepatic function, as follows:
Total bilirubin ≤ 1.5 x ULN
AST and ALT ≤ 5 x ULN
Exclusion Criteria
Exclusion Criteria:
Patients are currently on or have received anti-cancer therapy within the past 3 weeks.
Patients are currently on or have received radiation or local treatment within the past 3 weeks for the target lesion(s).
Patients have had major surgical procedures within 14 days prior to study entry.
Patients have a metastatic brain lesion(s), including asymptomatic and well controlled lesion(s).
Patients have malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications.
Patients have any history or presence of clinically significant condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results.
Patients have any history of other malignancy unless in remission for more than 1 year. (skin carcinoma and carcinoma-in-site of uterine cervix treated with curative intent is not exclusionary).
Female patients are pregnant or breast feeding.
Patients who been previously treated with varlitinib or have been previously treated with capecitabine as first line therapy for advanced or metastatic disease. For patients who have previously received capecitabine as radiosensitizer or as part of their adjuvant therapy and their disease has relapsed for more than 6 months after their last dose of capecitabine adjuvant therapy, their capecitabine therapy will not be considered as a line of systemic chemotherapy for metastatic/advanced disease, and thus they can participate in the study.
Patients have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication.
Patients have unresolved or unstable serious toxicity (≥CTCAE 4.03 Grade 2), with the exception of anemia, asthenia, and alopecia, from prior administration of another investigational drug and/or prior cancer treatment.
Patients have a known positive test for HIV, active hepatitis C, or hepatitis B infection with hepatitis B virus deoxyribonucleic acid exceeding 2000 IU/mL.
Patients have a known history of drug addiction within last 1 year, on the basis that there could be a higher risk of non-compliance to investigational product.
Patients need continuous treatment with proton pump inhibitors during the study period.
Patients have a baseline corrected QT interval QTc> 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, an unstable cardiac syndrome in the past 3 months before screening visit, > class 2 New York Heart Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone.
Patients are currently on or have received anti-cancer therapy within the past 3 weeks.
Patients are currently on or have received radiation or local treatment within the past 3 weeks for the target lesion(s).
Patients have had major surgical procedures within 14 days prior to study entry.
Patients have a metastatic brain lesion(s), including asymptomatic and well controlled lesion(s).
Patients have malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications.
Patients have any history or presence of clinically significant condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results.
Patients have any history of other malignancy unless in remission for more than 1 year. (skin carcinoma and carcinoma-in-site of uterine cervix treated with curative intent is not exclusionary).
Female patients are pregnant or breast feeding.
Patients who been previously treated with varlitinib or have been previously treated with capecitabine as first line therapy for advanced or metastatic disease. For patients who have previously received capecitabine as radiosensitizer or as part of their adjuvant therapy and their disease has relapsed for more than 6 months after their last dose of capecitabine adjuvant therapy, their capecitabine therapy will not be considered as a line of systemic chemotherapy for metastatic/advanced disease, and thus they can participate in the study.
Patients have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication.
Patients have unresolved or unstable serious toxicity (≥CTCAE 4.03 Grade 2), with the exception of anemia, asthenia, and alopecia, from prior administration of another investigational drug and/or prior cancer treatment.
Patients have a known positive test for HIV, active hepatitis C, or hepatitis B infection with hepatitis B virus deoxyribonucleic acid exceeding 2000 IU/mL.
Patients have a known history of drug addiction within last 1 year, on the basis that there could be a higher risk of non-compliance to investigational product.
Patients need continuous treatment with proton pump inhibitors during the study period.
Patients have a baseline corrected QT interval QTc> 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, an unstable cardiac syndrome in the past 3 months before screening visit, > class 2 New York Heart Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone.
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
68 participants
